Research and Markets has announced the addition of the "Anxiety Disorders - Pipeline Review, H2 2016" report to their offering.
Anxiety Disorders pipeline therapeutics constitutes close to 94 molecules. Out of which approximately 76 molecules are developed by Companies and remaining by the Universities
Institutes. Our latest report Anxiety Disorders - Pipeline Review, H2 2016, outlays comprehensive information on the therapeutics under development for Anxiety Disorders, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.
Anxiety Disorders Anxiety disorders are a group of mental illnesses that cause people to feel excessively frightened, distressed, or uneasy during situations in which most other people would not experience these same feelings. Symptoms include feelings of panic, fear, and uneasiness, problems sleeping, shortness of breath, heart palpitations, nausea, muscle tension and dizziness. Treatment includes antidepressant medications. The molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 5, 8, 7, 2, 45, 8 and 1 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 14 and 3 molecules, respectively.
Furthermore, this report also reviews of key players involved in therapeutic development for Anxiety Disorders and features dormant and discontinued projects.
Key Topics Covered:
For more information about this report visit http://www.researchandmarkets.com/research/j4x45n/anxiety_disorders
View source version on businesswire.com: http://www.businesswire.com/news/home/20161012005809/en/Business Wire
Last updated on: 12/10/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.